PMID- 35301934
OWN - NLM
STAT- MEDLINE
DCOM- 20220725
LR  - 20220727
IS  - 1744-764X (Electronic)
IS  - 1474-0338 (Linking)
VI  - 21
IP  - 6
DP  - 2022 Jun
TI  - Ayahuasca, a potentially rapid acting antidepressant: focus on safety and 
      tolerability.
PG  - 789-801
LID - 10.1080/14740338.2022.2054988 [doi]
AB  - INTRODUCTION: Ayahuasca is a psychedelic brew originally used by Amazonian 
      indigenous groups and in religious rituals. Pre-clinical and observational 
      studies have demonstrated its possible potential as an antidepressant, and open- 
      and placebo-controlled clinical trials corroborated these results. For it to 
      become an approved treatment for depression, its safety and tolerability need to 
      be assessed and documented. AREAS COVERED: We have gathered data regarding the 
      occurrence of adverse events (AEs) in all reported randomized, placebo-controlled 
      trials with healthy and clinical populations involving ayahuasca administration 
      (n = 108 ayahuasca administrations). We systematically categorized these results, 
      recorded their prevalence, and discussed the possible mechanisms related to their 
      emergence. EXPERT OPINION: There were no reports of serious AEs, indicating a 
      relative safety of ayahuasca administration in controlled settings. Most common 
      AEs included nausea, vomiting, headaches, and transient increases in 
      cardiovascular measurements. Ayahuasca research is still in its infancy, 
      especially concerning the absence of large and robust clinical trials to verify 
      its antidepressant effects. Dose standardization, legal prohibition of the 
      possession of its alkaloids and how traditional communities will be compensated 
      if ayahuasca becomes an approved medicine are the biggest obstacles to overcome 
      for its future use in the therapeutic context.
FAU - Rossi, Giordano Novak
AU  - Rossi GN
AUID- ORCID: 0000-0002-1952-1207
AD  - Department of Neurosciences and Behavior, Ribeirao Preto Medical School, 
      University of Sao Paulo, Ribeirao Preto, Brazil.
FAU - Dias, Isabella Caroline da Silva
AU  - Dias ICDS
AD  - Department of Neurosciences and Behavior, Ribeirao Preto Medical School, 
      University of Sao Paulo, Ribeirao Preto, Brazil.
FAU - Baker, Glen
AU  - Baker G
AD  - National Institute for Translational Medicine (INCT-TM) CNPq, Brazil.
AD  - Department of Psychiatry (Neurochemical Research Unit) and Neuroscience & Mental 
      Health Institute, University of Alberta, Edmonton, Alberta, Canada.
FAU - Bouso Saiz, Jose Carlos
AU  - Bouso Saiz JC
AUID- ORCID: 0000-0003-1115-9407
AD  - Department of Neurosciences and Behavior, Ribeirao Preto Medical School, 
      University of Sao Paulo, Ribeirao Preto, Brazil.
AD  - International Center for Ethnobotanical Education, Research and Services, 
      ICEERS,Barcelona, Spain.
AD  - Medical Anthropology Research Center (MARC), Universitat Rovira i Virgili, 
      Tarragona, Spain.
FAU - Dursun, Serdar M
AU  - Dursun SM
AD  - National Institute for Translational Medicine (INCT-TM) CNPq, Brazil.
AD  - Department of Psychiatry (Neurochemical Research Unit) and Neuroscience & Mental 
      Health Institute, University of Alberta, Edmonton, Alberta, Canada.
FAU - Hallak, Jaime E C
AU  - Hallak JEC
AD  - Department of Neurosciences and Behavior, Ribeirao Preto Medical School, 
      University of Sao Paulo, Ribeirao Preto, Brazil.
AD  - National Institute for Translational Medicine (INCT-TM) CNPq, Brazil.
AD  - Department of Psychiatry (Neurochemical Research Unit) and Neuroscience & Mental 
      Health Institute, University of Alberta, Edmonton, Alberta, Canada.
FAU - Dos Santos, Rafael G
AU  - Dos Santos RG
AUID- ORCID: 0000-0003-2388-4745
AD  - Department of Neurosciences and Behavior, Ribeirao Preto Medical School, 
      University of Sao Paulo, Ribeirao Preto, Brazil.
AD  - National Institute for Translational Medicine (INCT-TM) CNPq, Brazil.
AD  - International Center for Ethnobotanical Education, Research and Services, 
      ICEERS,Barcelona, Spain.
LA  - eng
PT  - Journal Article
DEP - 20220323
PL  - England
TA  - Expert Opin Drug Saf
JT  - Expert opinion on drug safety
JID - 101163027
RN  - 0 (Antidepressive Agents)
SB  - IM
MH  - *Antidepressive Agents/adverse effects
MH  - *Banisteriopsis/adverse effects
MH  - Humans
MH  - Randomized Controlled Trials as Topic
OTO - NOTNLM
OT  - adverse events
OT  - antidepressant
OT  - ayahuasca
OT  - safety
EDAT- 2022/03/19 06:00
MHDA- 2022/07/26 06:00
CRDT- 2022/03/18 08:39
PHST- 2022/03/19 06:00 [pubmed]
PHST- 2022/07/26 06:00 [medline]
PHST- 2022/03/18 08:39 [entrez]
AID - 10.1080/14740338.2022.2054988 [doi]
PST - ppublish
SO  - Expert Opin Drug Saf. 2022 Jun;21(6):789-801. doi: 10.1080/14740338.2022.2054988. 
      Epub 2022 Mar 23.